ASCO GU 2019
ASCO GU 2019
- ASCO GU 2019: LATITUDE Study - Final Analysis of Phase III Study in Patients with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer
- ASCO GU 2019: Transitional Surrogate Endpoint for Survival in Phase II Trials for mCRPC - Assessment of Circulating Tumor Cell Number
- ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
- ASCO GU 2019: Pembrolizumab in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2019: PROSPER: Comparing Perioperative Nivolumab versus Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
ASCO GU 2019 Kidney Cancer
- ASCO GU 2019: Results from KEYNOTE-427 Cohort B: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma
- ASCO GU 2019: Phase III KEYNOTE-426 Study: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Locally Advanced or Metastatic Renal Cell Carcinoma
- ASCO GU 2019: Phase III CheckMate 214 Trial of First-Line Nivolumab + Ipilimumab or Sunitinib in Patients with Advanced Renal Cell Carcinoma with Thirty Month Follow Up Results
- ASCO GU 2019: Final analysis from the NIVOREN GETUG AFU 26 study — Safety and Efficacy of Nivolumab in Metastatic Renal Cell Carcinoma
- ASCO GU 2019: CheckMate 214 Trial - Thirty Month Follow-up of First-line Nivolumab + Ipilimumab or Sunitinib in Patients with Advanced Renal Cell Carcinoma
ASCO GU 2019 Bladder Cancer
- ASCO GU 2019: Phase II Trial of Pembrolizumab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to BCG
- ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma
- ASCO GU 2019: Gemcitabine-Carboplatin versus Gemcitabine-Oxaliplatin In Cisplatin Un-Fit Advanced Urothelial Carcinoma: Randomized Phase II Study-COACH Study
- ASCO GU 2019: CheckMate 9UT - Nivolumab or Nivo Plus BMS-986205 with or without Intravesical Bacillus Calmette-Guerin in BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
- ASCO GU 2019: POTOMAC Study - Durvalumab and BCG versus BCG Alone in High-risk, BCG-Naïve Non Muscle-Invasive Bladder Cancer
ASCO GU 2019 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2019: Fierce-21: Phase II Study of Vofatamab, a Selective Inhibitor of FGFR3, as Salvage Therapy in Metastatic Urothelial Carcinoma
- ASCO GU 2019: Health-Related Quality of Life Reporting in Phase III Randomized Controlled Trials of Metastatic Prostate Adenocarcinoma and Urothelial Carcinoma
- ASCO GU 2019: Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
- ASCO GU 2019: Phase II Study of Ribociclib in Men with Unresectable, Incurable Teratoma with Recent Progression
- ASCO GU 2019: Accelerated versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors
ASCO GU 2019 Press Releases
- Seattle Cancer Care Alliance Physicians to Present their Research at Genitourinary Cancers Symposium
- ASCO GU 2019: Phase 3 Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: The ARCHES Trial
- MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis
- ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019
- Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
